Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for co…
This bill adds xylazine (including salts and isomers) to Schedule III of the Controlled Substances Act, with explicit definitions and exceptions for legitimate veterinary and wildlife uses. It phases in certain regulatory requirements, exempts existing manufacturers from immediate capital security upgrades, requires DEA/FDA to facilitate manufacturer transitions, adds xylazine to ARCOS reporting, asks the Sentencing Commission to review penalties, and mandates reports to Congress at 18 months and four years on illicit xylazine prevalence, sources, and analogues.
Progressives emphasize public-health and harm-reduction needs
Relative to its intended legislative type, this bill is a clearly drafted substantive statutory amendment to add xylazine to Schedule III, with specific implementing provisions, transition timelines, and reporting requirements, but it provides minimal problem statement and omits fiscal/resourcing discussion.
This bill adds xylazine (including salts and isomers) to Schedule III of the Controlled Substances Act, with explicit definitions and exceptions for legitimate veterinary and wildlife uses.
It phases in certain regulatory requirements, exempts existing manufacturers from immediate capital security upgrades, requires DEA/FDA to facilitate manufacturer transitions, adds xylazine to ARCOS reporting, asks the Sentencing Commission to review penalties, and mandates reports to Congress at 18 months and four years on illicit xylazine prevalence, sources, and analogues.
Targeted public-health and law-enforcement measure with practical exemptions increases chances, but sentencing impacts and federal procedural barriers reduce certainty.
Relative to its intended legislative type, this bill is a clearly drafted substantive statutory amendment to add xylazine to Schedule III, with specific implementing provisions, transition timelines, and reporting requirements, but it provides minimal problem statement and omits fiscal/resourcing discussion.
Progressives emphasize public-health and harm-reduction needs
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize public-health and harm-reduction needs
Likely supportive of controlling a dangerous illicit adulterant while wary of criminalization.
Views tracking and federal study positively but insists on treatment and harm-reduction framing.
Concerned sentencing reviews could increase incarceration without treatment funding.
Pragmatic support with caution.
Values scheduled control, data collection, and transition periods, but wants clarity on costs, enforcement priorities, and sentencing consequences.
Favors monitoring outcomes before stronger measures.
Mixed reaction: supportive of measures that curb illicit drugs and increase enforcement, but skeptical of federal regulatory expansion affecting vets and manufacturers.
Worries about added bureaucracy and possible small-business costs.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Targeted public-health and law-enforcement measure with practical exemptions increases chances, but sentencing impacts and federal procedural barriers reduce certainty.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize public-health and harm-reduction needs
Targeted public-health and law-enforcement measure with practical exemptions increases chances, but sentencing impacts and federal procedur…
Relative to its intended legislative type, this bill is a clearly drafted substantive statutory amendment to add xylazine to Schedule III, with specific implementing provisions, transition timelines, and reporting requi…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.